When was CancerCell founded?

CancerCell was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is CancerCell located?

CancerCell is headquartered in Los Angeles, United States.

Who is the current CEO of CancerCell?

Howard Leonhardt of CancerCell.

Is CancerCell a funded company?

CancerCell is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on May 19, 2019.

When was the latest funding round of CancerCell?

CancerCell's latest funding was a $***** Seed round on May 19, 2019, with participation from 1 investor. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $1.3B in funding in 2026 to date.

Where does CancerCell rank among its competitors?

CancerCell ranks 1687th amongst 2041 active competitors, of which 452 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was LifeMine Therapeutics, which secured $75M in Aug, 2026.

Who are the top competitors of CancerCell?

CancerCell's top competitors include Antheia, Transcenta and Akeso. Among them, LifeMine Therapeutics secured the most recent funding round in August, 2026.

CancerCell - 2026 Company Profile, Team, Funding & Competitors

Company Details

CancerCell offers personalized bioelectric cancer tumor eradication therapy. The company has developed a patented technology which enables to detect cancer tumors and deliver individualized bioelectric signals to jam the ability of the tumor to communicate and change the surface proteins of the tumor so that the person’s own body can attack it.

Website: cancercellinc.com
Phone Number: +1 **********
Part Of

Key Metrics

Founded Year

2018

Location

Los Angeles, United States

Stage

Seed

Latest Funding Round

Seed, May 19, 2019, $*****

Investors

Leonhardt Ventures

Ranked

1687^th among 2041 active competitors

Similar Companies

Antheia & 2750 more

View CancerCell's full profile

CancerCell has raised funding over 1 round. Its latest funding round was a Seed round on May 19, 2019 for $*****. 1 investor participated in its latest round. CancerCell has 1 institutional investor.

Here is the list of recent funding rounds of CancerCell:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 19, 2019	7237642	Seed	7458527	6106884	3939982	1162083

Access funding benchmarks and valuations. Sign up today!

View details of CancerCell's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CancerCell include Antheia, Transcenta and Akeso. Here is the list of Top 10 competitors of CancerCell, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
2nd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
3rd	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Loayal Valley Capital, Sino Biopharmaceutical ... & 18 others	65/100
4th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 14 others	64/100
5th	Axol Bioscience 2013, Cambridge (United Kingdom), Series A	Provider of human cells, reagents, and reprogramming services	$13.3M	Calculus Capital, Scottish Enterprise & 13 others	64/100
6th	Novogene Corporation 2011, Beijing (China), Series B	Provider of genomic services and solutions	$75M	SDIC Innovation, CMB International Capital ... & 4 others	64/100
7th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 14 others	63/100
8th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	TA Associates, UBS & 1 others	63/100
9th	LifeMine Therapeutics 2016, Watertown (United States), Series E	Developer of novel drugs from fungi via genome mining and recombinant overexpression	$563M	Fidelity Investments, 6 Dimensions Capital ... & 17 others	63/100
10th	Novocure 2000, Haifa (Israel), Public	Developer of therapeutics to treat solid tumours	$10M	Johnson & Johnson Innovation – JJDC, Pfizer Venture Investments ... & 13 others	63/100
1687th	CancerCell 2018, Los Angeles (United States), Seed	Developer of personalized bioelectric cancer tumor eradication therapy	-	Leonhardt Ventures	22/100